Copyright
©The Author(s) 2025.
World J Transplant. Mar 18, 2025; 15(1): 98975
Published online Mar 18, 2025. doi: 10.5500/wjt.v15.i1.98975
Published online Mar 18, 2025. doi: 10.5500/wjt.v15.i1.98975
Total population (n = 91) | SOT (n = 28) | HSCT (n = 63) | χ² | P value | |
Age at admission (years) | 56 (43.2-64.7) | 61 (51.5-68) | 54 (40.5-61) | NA | < 0.01 |
Age at transplantation (years) | 50 (36.2-59) | 50 (36.7-58.2) | 51 (35-60) | NA | 0.86 |
Male gender | 55 (60.4) | 17 (60.7) | 38 (60.3) | 0.001 | 0.97 |
Comorbidities | |||||
Cardiovascular | 56 (61.5) | 26 (92.9) | 30 (47.6) | 16.76 | < 0.01 |
Respiratory | 13 (14.3) | 3 (10.7) | 10 (15.9) | NA | 0.51 |
Chronic kidney disease | 34 (37.4) | 26 (92.9) | 8 (12.7) | 53.22 | < 0.01 |
Chronic hemodialysis | 11 (12.1) | 9 (32.1) | 2 (3.2) | NA | < 0.01 |
Diabetes | 16 (17.6) | 7 (25) | 9 (14.3) | 1.53 | 0.21 |
Malignant disease | 11 (12.1) | 4 (14.3) | 7 (11.1) | NA | 0.70 |
Disease severity | |||||
SOFA | 9 (6-11) | 7.5 (5-11) | 9 (7-10) | NA | 0.37 |
APACHE II | 22 (17.5-27) | 19 (14-22) | 23 (19-27) | NA | 0.01 |
Respiratory support | 48 (52.7) | 12 (42.9) | 36 (57.1) | 1.58 | 0.20 |
Vasoactive medication support | 32 (35.2) | 9 (32.1) | 23 (36.5) | 0.16 | 0.68 |
Total population (n = 91) | SOT (n = 28) | HSCT (n = 63) | |
Mechanical ventilation | 73 (80.2) | 18 (64.3) | 55 (87.3)a |
Vasoactive medication support | 65 (71.4) | 13 (46.4) | 52 (82.5)a |
Acute renal replacement therapy | 51 (56) | 21 (75) | 30 (47.6)a |
ICU survival | 24 (26.4) | 16 (57.1) | 8 (12.7)a |
7 days survival | 49 (53.8) | 22 (78.6) | 27 (42.9)a |
28 days survival | 36 (39.6) | 21 (75) | 15 (23.8)a |
60 days survival | 27 (29.7) | 18 (64) | 9 (14.3)a |
ICU LOS | 7 (3-17) | 9.5 (3-26) | 7 (3.2-16) |
Hospital LOS | 28 (12-48.7) | 35.5 (17.2-48.7) | 22 (11.2-48.7) |
Sepsis/ septic shock (n = 53) | Other diagnoses (n = 38) | |
Age at admission | 55 (43.5-63.2) | 57 (46-65) |
Age at transplantation | 50 (36.7-58.2) | 54 (41-59) |
Male gender | 30 (56.6) | 25 (65.8) |
Comorbidites | ||
Cardiovascular | 32 (60.4) | 24 (63.2) |
Respiratory | 5 (9.4) | 8 (21.1) |
Chronic kidney disease | 18 (34.0) | 16 (42.1)a |
Chronic hemodialysis | 4 (7.5) | 7 (18.4) |
Diabetes | 10 (18.9) | 6 (15.8) |
Malignant disease | 7 (13.2) | 4 (10.5) |
Respiratory support at admission | 27 (50.9) | 21 (55.3) |
Vasoactive medication support at admission | 26 (49.1) | 6 (15.8)a |
APACHE II | 24.5 (19-28) | 19.5 (15.5-23)a |
SOFA | 9 (7-12.5) | 8 (5-9)a |
Acute renal replacement therapy | 35 (66.0) | 16 (42.1)a |
Mechanical ventilation | 47 (88.7) | 26 (68.4)a |
Vasoactive medication support | 47 (88.7) | 18 (47.4)a |
ICU LOS | 8 (4-17) | 5 (2-16) |
Hospital LOS | 30 (14.5-52.5) | 19 (11-45) |
ICU survival | 8 (15.1) | 16 (42.1)a |
7 days survival | 22 (41.5) | 27 (71.1)a |
28 days survival | 15 (28.3) | 21 (55.3)a |
60 days survival | 10 (18.9) | 17 (44.7)a |
- Citation: Vujaklija Brajkovic A, Kosuta I, Batur L, Sundalic S, Medic M, Vujevic A, Bielen L, Babel J. Patients admitted in the intensive care unit after solid organ or bone marrow transplantation: Retrospective cohort study. World J Transplant 2025; 15(1): 98975
- URL: https://www.wjgnet.com/2220-3230/full/v15/i1/98975.htm
- DOI: https://dx.doi.org/10.5500/wjt.v15.i1.98975